Overview
Cancer doesn't always spread randomly—certain cancers preferentially spread to specific organs, a phenomenon called "organotropism." In metastatic lung cancer, understanding these patterns could provide insights into disease biology and help predict which organs are at risk during follow-up, informing surveillance strategies and treatment decisions.
Researchers used Flatiron Health’s US Non-Small Cell Lung Cancer (NSCLC) Clinico-Genomic Database, inclusive of more than 337,000 patients with NSCLC, to analyze real-world and genomic data from over 11,500 patients with metastatic NSCLC across 18 different metastatic sites. They found that 73% of patients developed metastases in two or more organ sites, and certain initial metastatic locations predicted secondary site involvement—for example, patients with initial adrenal metastases were 43% more likely to develop brain metastases compared with any other site. Two distinct patterns of high metastatic burden were identified: one pattern involving brain, bone, lung, and liver spread associated with better median overall survival (11.8 months), and another pattern involving bone, lymph nodes, adrenal, soft tissue, and liver associated with worse survival (10.2 months). The better-outcome group had unique mutations rarely seen in site-specific disease.
Why this matters
This comprehensive analysis of metastatic progression patterns provides oncologists with valuable insights into disease behavior and prognosis. By recognizing distinct patterns of organ spread and their molecular drivers, physicians can better counsel patients about what to expect and potentially identify opportunities for more intensive surveillance or preventive treatment strategies. This framework could ultimately help improve outcomes by enabling more informed, personalized approaches to managing advanced lung cancer.